Functional inactivation of tuberous sclerosis 2 gene (Tsc2) leads to renal carcinogenesis in the hereditary renal carcinoma Eker rat models. Recent studies revealed a role of tuberin, a TSC2 product, in suppressing the p70 S6 kinase (p70S6K) activity via inhibition of mammalian target of rapamycin (mTOR). Phosphorylated S6 protein, a substrate of p70S6K, was expressed in the early lesions in Eker rats, and this expression was suppressed by the treatment of rapamycin, an inhibitor of mTOR. We previously isolated the novel gene Niban expressed in renal carcinogenesis of Eker rats. In this study, we demonstrated that the expression of Niban was detected from early preneoplastic lesions in Eker rats. Interestingly, in contrast to the phosphorylated S6 protein, the expression of Niban was unchanged and early lesions still remained even after treatment with rapamycin. These results might suggest the existence of another pathway independent of mTOR-S6K pathway in Tsc2 mutant renal carcinogenesis. In addition, Niban was also expressed in other renal carcinoma models, including Tsc1 and Tsc2 knockout mice, and various types of human renal cell carcinomas. Thus, Niban was commonly expressed in renal carcinomas and might be a new marker for renal carcinogenesis.
Introduction
Hereditary renal carcinoma in the rat, originally reported by R Eker in 1954, is an example of a specific cancer in an experimental animal (Eker and Mossige, 1961) . We and others have demonstrated that the gene responsible for renal carcinoma in the Eker rat is the rat homologue of the human TSC2 gene. In the Eker rat, one of the Tsc2 allele is inactivated genetically by the insertion of a transposon-like sequence (Hino et al., 1994; Yeung et al., 1994; Kobayashi et al., 1995) . At the histological level, multiple stages in the development of renal carcinomas have been observed, beginning with isolated, phenotypically altered renal tubules (Hino et al., 1993) . We have demonstrated the inactivation of the wild-type Tsc2 allele in phenotypically altered renal tubules and provided evidence that two-hit mutation of the Tsc2 gene is the causative step in renal carcinogenesis .
Carcinogenesis consists of multiple steps and carcinoma development is associated with multiple genetic alterations even in hereditary cancers. Although the inactivation of Tsc2 results in the initiation of renal carcinogenesis, it is not sufficient for tumor progression. Progression to carcinomas may require additional genetic and epigenetic modification . To identify the genes associated with multistep renal carcinogenesis, we previously performed the differential display analysis for two cell lines established from the Eker rat renal carcinoma, and isolated the novel gene Niban (Majima et al., 2000) . The Niban gene consists of 14 exons and is located on rat chromosome 13, or mouse and human chromosome 1.
Recent biochemical analyses revealed that tuberin, the TSC2 gene product, is a substrate of Akt and can inhibit the phosphatidylinositol 3-kinase (PI3K)-dependent activation of p70 S6 kinase (p70S6K) via the inhibition of mammalian target of rapamycin (mTOR) (Dan et al., 2002; Gao et al., 2002; Inoki et al., 2002; Manning et al., 2002) . The phosphorylated form of S6 ribosomal protein, a substrate of p70S6K, was expressed in early preneoplastic lesions in Eker rats, and the expression of this phosphorylated protein was suppressed by treatment with rapamycin, an inhibitor of mTOR (Kenerson et al., 2002; Kobayashi et al., 2003) .
In this study, we demonstrated that the expression of Niban was also detected in early preneoplastic lesions in Eker rats. Interestingly, the expression of Niban was unchanged and Niban-positive early preneoplastic lesions still remained after treatment with rapamycin. Furthermore, Niban was commonly expressed in other renal carcinogenesis models and sporadic human renal carcinomas.
ONCOGENOMICS

Results
Demonstration of the specificity of anti-rat and human Niban polyclonal antibodies
For the detection of Niban proteins, we generated rabbit polyclonal antibodies against rat or human Niban proteins. First, we assessed the specificity of these polyclonal antibodies by Western blotting and immunohistochemical analysis (Figure 1) . The predicted size of Niban proteins was about 130 kDa. This predicted size was clearly detected in extracts from HeLa cells and NIH3T3 cells transiently transfected with plasmids expressing the rat or human Niban proteins, respectively. This band could not be detected in extracts from cells transiently transfected with empty vector (Figures 1a and b ; lanes R and E). The expression of rat Niban was not detected in normal kidneys from nonEker rats (Figure 1a ; lane C). Interestingly, the smaller band (about 70 kDa) was detected in renal tumors from Eker rats, and this band disappeared with the addition of the antigen peptide by Western blotting analysis ( Figure 1a ; lanes 1-3). Next, we examined the specificity of antibody against human Niban using cell lines established from human renal cell carcinomas. Two bands (about 70 and 130 kDa) were detected, and both of these bands disappeared with the addition of the antigen peptide (Figure 1b; lanes 1-3) . The same results were obtained from immunohistochemical analyses (Figures 1c-f) . Thus, we consider that these antibodies specifically react with a peptide corresponding to the internal sequences of rat or human Niban proteins.
Expression of Niban is detected from the early stage of renal carcinogenesis in Eker rats
Next, we examined the expression of Niban in renal tumors developed in Eker rats using anti-rat Niban antibody. In the proximal tubules of normal kidneys from non-Eker rats, we could not detect the expression of Niban (Figure 2a ). Strong staining was observed in phenotypically altered renal tubules, hyperplasias and adenomas (Figures 2b-d) . A brush border was identified in phenotypically altered renal tubules (Figure 2b , arrow), so we considered that these renal tumors were derived from the proximal tubules. In advanced adenocarcinoma, we identified two groups, which revealed positive or negative expressions of Niban (Figure 2e ).
Expression of Niban is commonly induced in renal carcinomas
After we checked the crossreactivity of anti-rat Niban antibody between rat and mouse Niban proteins, we analysed the expression of Niban in other renal carcinogenesis models, including Tsc1 ( Figure 3a ) and Tsc2 knockout mouse ( Figure 3b ). The expression of Niban was also detected in renal tumors developed in these models. Furthermore, we can detect the expression of Niban in the sporadic human renal cell carcinomas Phosphorylated S6-negative and Niban-positive early preneoplastic lesions are detected in the Eker rat after treatment with rapamycin Similar results were obtained with regard to the expression of phosphorylated form of S6 ribosomal protein in the renal tumors developed in Eker rats. This phosphorylated protein was detected in the early preneoplastic lesions (Kenerson et al., 2002) . Our data also showed the expression of phosphorylated S6 protein in Eker rats (Figures 4a and b) . Compared with the immunostaining of Niban, however, lesions that did not express phosphorylated S6 were also observed (Figures 4c and d, arrow) . Interestingly, when treated with the rapamycin, the Niban expression remained (Figures 4f and h ), while the expression of phosphorylated S6 was suppressed (Figures 4e and g ).
Niban protein expression was not affected by treatment with rapamycin in the renal tumor cell lines with wild-type and mutant Tsc2
To confirm the result that inactivation of S6K activity did not affect Niban protein level in primary renal tumors in Eker rats, we compared the expression levels of Niban in the presence and absence of rapamycin in the renal tumor cell lines with wild-type and mutant Tsc2 ( Figure 5 ). Phosphorylation of S6 ribosomal protein at Ser 235/236 was suppressed by treatment with rapamycin. In contrast to phosphorylation status of S6 protein, however, the expression level of Niban was unchanged even after treatment with rapamycin in all renal tumor cell lines. 
Discussion
Hereditary cancers are important in understanding carcinogenesis. We have demonstrated that inactivation of Tsc2 is the causative step in a hereditary renal carcinoma Eker rat model (Hino et al., 1994; Yeung et al., 1994; Kobayashi et al., 1995; Kubo et al., 1995) . However, progression to carcinomas may require additional genetic and epigenetic modification . We previously isolated the novel gene Niban expressed in the early stage of renal carcinogenesis (Majima et al., 2000) . In this study, we generated antibodies against rat or human Niban proteins and evaluated the expression of Niban in hereditary renal carcinomas and sporadic human renal cell carcinomas (Figures 2 and 3) . Interestingly, Niban was expressed even in early preneoplastic lesions in the hereditary renal carcinomas, including Eker rats (Figures 2b-e) , and Tsc1 ( Figure 3a) and Tsc2 knockout mice (Figure 3b ). In addition, Niban was also expressed in other renal carcinogenesis models, for example, Nihon rats (Okimoto et al., 2000; Hino et al., 2001) and simian virus (SV) 40 large T antigen transgenic rats (Takahashi et al., 1999) (unpublished observation). In the sporadic human cases, we can also detect the expression of Niban (Figures 3c-f ). These renal cell carcinomas consist of the various types, including clear cell carcinomas, granular cell carcinomas and spindle cell carcinomas, and have no loss of heterozygosity of the TSC2 gene (unpublished observation). These findings suggest that the expression of Niban is commonly induced at the early stage of renal carcinogenesis, independent of the TSC2 status.
Recent genetic studies in Drosophila indicate that the products of TSC1 and TSC2, hamartin and tuberin, respectively, may regulate cell size and cell cycle via the insulin/p70S6K pathway (Gao and Pan, 2001; Potter et al., 2001; Tapon et al., 2001) . In mammalian cells, the complex of hamartin and tuberin may be associated with the downregulation of S6K by inhibition of mTOR (Dan et al., 2002; Gao et al., 2002; Inoki et al., 2002; Manning et al., 2002) . In the Eker rat, this inhibition was released and the phosphorylated form of S6 ribosomal protein was expressed in the early preneoplastic lesions (Figures 4a and b) . Importantly, the expression of Niban was observed more frequently than that of phosphorylated S6 protein (Figures 4c and d) . Kenerson et al. (2002) reported on the effect of rapamycin, an inhibitor of mTOR, on renal tumors in the Eker rat. We also reported on the effect of rapamycin in tumor formation by a transplantation system using a Tsc2-deficient renal tumor cell line in Niban expressed in renal carcinogenesis H Adachi et al nude mice . In that system, the phosphorylated form of S6 was dramatically reduced in rapamycin-treated tumors, and these tumors showed both apoptotic and necrotic appearance. In this study using the primary renal tumors developed in Eker rats, the phosphorylated form of S6 was also reduced by treatment with rapamycin. However, early preneoplastic lesions with the expression of Niban still remained in the Eker rat after treatment with rapamycin (Figures 4e-h ). In addition, the expression level of Niban was unchanged even after treatment with rapamycin in the renal tumor cell lines with wild-type and Tsc2 mutant ( Figure 5 ). These results indicate that another pathway, independent of the mTOR-S6 pathways, could be involved in renal carcinogenesis in Eker (Tsc2 mutant) rats, and inactivation of S6K activity did not affect Niban protein level. The function of Niban and the physiological pathways through which it acts still remain to elucidate. To answer this question, we first performed sequencing and homology evaluation with BLAST and FASTA programs. This Niban protein contains a dnaJ motif sequencing, which is a family of heat-shock protein upregulated under stress conditions. In normal culture conditions, Niban was detected in a size of about 130 kDa in LK9d(L) cells, established from Eker rat renal tumors. By the addition of stress, for example, heat shock, oxidative stress, hypertonic stress and administration of endotoxin (lipopolysaccharide), small size of Niban protein, about 70 kDa, was also detected in LK9d(L) cells in addition to the 130 kDa, and was upregulated time dependently. Niban protein might have undergone the processing under stress conditions. Furthermore, Niban protein moves from the cytoplasm to the nucleus under stress conditions by immunocytochemical analysis (unpublished observation). According to our preliminary data, overexpression of Niban itself does not accelerate cell proliferation at least in the transient status. Niban was strongly upregulated in the early stage of renal carcinogenesis, and might function as a protector against cell death under stress conditions of carcinogenesis.
In conclusion, the present study demonstrates that Niban is commonly expressed in early preneoplastic lesions in all the renal carcinogenesis models examined so far. Furthermore, Niban is also expressed in the various types of human renal cell carcinomas. Therefore, this Niban might be a good marker for renal carcinogenesis, especially at the early stage. Future study of its molecular function should provide new insights into multistep renal carcinogenesis.
Materials and methods
Tissues
Tissues were dissected from normal kidneys of non-Eker rats, and primary renal tumors developed in Eker rats (Eker and Mossige, 1961) , Tsc1 (Kobayashi et al., 2001) and Tsc2 knockout mice (Kobayashi et al., 1999) . In addition, tissues from patients with primary renal cell carcinomas who underwent total nephrectomy were also included in this study. Each tissue sample was fixed in 10% neutral-buffered formalin. After embedding in paraffin wax, they were cut into 3-mm-thick sections and used for histopathological assessment. Total protein was extracted from normal kidneys of non-Eker rats and primary renal tumors developed in Eker rats to use the Western blotting analysis. This study was performed according to the principles of laboratory animal care, and informed consent was obtained from the patients.
Cell lines and culture conditions
Three renal tumor cell lines, which were CACL1-111, MKOC1-277 and NR-22, were used to evaluate the effect of rapamycin on the expression level of Niban protein in this study. CACL1-111 and MKOC1-277 were established from renal tumors of Tsc1 and Tsc2 knockout mice, respectively, and were maintained in RPMI1640 medium supplemented with 10% fetal calf serum. NR-22 was established from renal tumors of Nihon rats, and were maintained in D-MEM medium supplemented with 10% fetal calf serum. Human renal tumor cell line, O-155, was used to analyse the specificity of anti-human Niban polyclonal antibody, and were maintained in MEM-Joklik medium supplemented with 10% fetal calf serum. Cells were harvested and total protein was analysed by Western blotting analysis.
Antibodies and chemicals
Synthetic peptides corresponding to the internal sequence of rat or human Niban were prepared. These peptides are located at the region encoded by exon 7 of rat Niban (TDLLPKLKGKKNDRKRA) and the carboxy-terminal end of human Niban (EGEGGAESFPELPSEE), respectively. The cysteine residue was introduced at the amino-terminal end of these peptides and coupled to thyroglobulin. The peptide and thyroglobulin complex was immunized to rabbits. Purification of the antibody was performed as described previously (Kon et al., 2000) . The antibody for phospho-S6 (Ser 235/236) ribosomal protein and actin were purchased from Cell Signaling Technology Inc. (Beverly, MA, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA), respectively. Rapamycin, RPMI1640 medium and MEM-Joklik medium were purchased from Sigma Chemical (St Louis, MO, USA). D-MEM medium was purchased from Invitrogen life technology (Carlsbad, CA, USA).
Administration of rapamycin
Rapamycin was injected intraperitoneally into male Eker rats (1 year of age) once daily for 3 consecutive days. The treated rats were given rapamycin at two dose levels (0.3 and 1.0 mg/kg). This method was performed according to a previous report by Kenerson et al. (2002) . To confirm the effect of rapamycin on Niban protein level, cells were incubated with 20 nM rapamycin for 16 h. The control animals and cells were given the same volume of dimethyl sulfoxide used as a vehicle.
Western blotting analysis
Extracted total proteins were separated by 10% SDS polyacrylamide gel electrophoresis (SDS-PAGE). The separated proteins were then transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore Corporation, Bedford, MA, USA). The membranes were incubated with primary antibodies. As a protein loading control, the membrane was also incubated with anti-actin antibody (1 : 1000 dilution). For demonstration of the specificity of anti-rat or human Niban antibodies, the membrane was incubated with antibodies with or without prior adsorption by the relevant specific peptide. Signals were visualized using ECL chemiluminescence substrate (Amersham Pharmacia Biotech, Buckinghamshire, UK) according to the manufacturer's manual.
Immunohistochemical analysis
The expression of Niban protein and the phosphorylated form of S6 ribosomal protein in the primary renal tumor tissues were detected using a three-step streptavidin-biotin-immunoperoxidase staining method. Before staining, deparaffinized tissue sections were preheated in 10 mM citrate buffer (pH 6.0), and exposed to 3% hydrogen peroxide. Then, the sections were incubated with the primary antibody overnight at room temperature, and stained using the streptavidin-biotinperoxidase complex. For controls, the sections were incubated with primary antibody preadsorbed with the relevant specific peptide.
